Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced that its Phase 3 LAGOON trial evaluating Zepzelca (lurbinectedin) in patients with relapsed small ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE